CureVac Q2 2023 Earnings Report $4.10 -0.08 (-1.91%) As of 01/17/2025 04:00 PM Eastern Earnings HistoryForecast CureVac EPS ResultsActual EPS-$0.33Consensus EPS -$0.28Beat/MissMissed by -$0.05One Year Ago EPSN/ACureVac Revenue ResultsActual Revenue$8.25 millionExpected Revenue$14.89 millionBeat/MissMissed by -$6.64 millionYoY Revenue GrowthN/ACureVac Announcement DetailsQuarterQ2 2023Date8/17/2023TimeN/AConference Call ResourcesPress ReleaseCVAC Earnings HistoryPowered by CureVac Earnings HeadlinesWhy CureVac (CVAC) Shares Are VolatileJanuary 10, 2025 | benzinga.comCureVac: Latest GBM Data Bodes Well For Next Program Check PointJanuary 8, 2025 | seekingalpha.comFree Stock Ticker Inside: This Indicator Caught Nvidia’s RalliesI’m not one to make super bold statements… But today, I’m making an exception. Because I’m 100% convinced this is the best indicator I’ve used for trading Nvidia… Don’t believe me? Just take a look at the last two rallies: This powerful indicator caught both moves almost perfectly.January 21, 2025 | ProsperityPub (Ad)Why CureVac (CVAC) Stock Is MovingJanuary 8, 2025 | benzinga.comArbutus could benefit from Big Pharma bird flu vaccines: JefferiesJanuary 8, 2025 | msn.comModerna stock gains on rising flu casesJanuary 7, 2025 | in.investing.comSee More CureVac Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CureVac? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CureVac and other key companies, straight to your email. Email Address About CureVacCureVac (NASDAQ:CVAC) N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.View CureVac ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings ICICI Bank (1/22/2025)Kinder Morgan (1/22/2025)Amphenol (1/22/2025)Abbott Laboratories (1/22/2025)Johnson & Johnson (1/22/2025)Procter & Gamble (1/22/2025)Travelers Companies (1/22/2025)Progressive (1/22/2025)GE Vernova (1/22/2025)CSX (1/23/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
